Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Patricia Hirano resigned as Senior Vice President, Regulatory Affairs at SOLENO THERAPEUTICS INC.
- Action
- resigned
- Role
- Senior Vice President, Regulatory Affairs
Exact text from the filing
each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Mark Hahn resigned as Director at SOLENO THERAPEUTICS INC.
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair and Dawn Bir resigned from his or her respective positions as a member of the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Andrew Sinclair resigned as Director at SOLENO THERAPEUTICS INC.
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair and Dawn Bir resigned from his or her respective positions as a member of the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Anish Bhatnagar resigned as Chief Executive Officer at SOLENO THERAPEUTICS INC.
- Action
- resigned
- Role
- Chief Executive Officer
Exact text from the filing
each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Anish Bhatnagar resigned as Director at SOLENO THERAPEUTICS INC.
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair and Dawn Bir resigned from his or her respective positions as a member of the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kristen Yen resigned as Senior Vice President, Global Clinical Operations & Patient Advocacy at SOLENO THERAPEUTICS INC.
- Action
- resigned
- Role
- Senior Vice President, Global Clinical Operations & Patient Advocacy
Exact text from the filing
each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Darin M. Lippoldt was appointed as President and Secretary at SOLENO THERAPEUTICS INC.
- Action
- appointed
- Role
- President and Secretary
Exact text from the filing
the officers of the Company are as follows: Darin M. Lippoldt (President and Secretary) and Matthew C. Abernethy (Treasurer and Vice President).
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Matthew Pauls resigned as Director at SOLENO THERAPEUTICS INC.
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair and Dawn Bir resigned from his or her respective positions as a member of the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jennifer Fulk resigned as Chief Financial Officer at SOLENO THERAPEUTICS INC.
- Action
- resigned
- Role
- Chief Financial Officer
Exact text from the filing
each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kevin Norrett resigned as Chief Business Officer at SOLENO THERAPEUTICS INC.
- Action
- resigned
- Role
- Chief Business Officer
Exact text from the filing
each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Matthew C. Abernethy was appointed as Treasurer and Vice President at SOLENO THERAPEUTICS INC.
- Action
- appointed
- Role
- Treasurer and Vice President
Exact text from the filing
the officers of the Company are as follows: Darin M. Lippoldt (President and Secretary) and Matthew C. Abernethy (Treasurer and Vice President).
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Matthew C. Abernethy was appointed as Director at SOLENO THERAPEUTICS INC.
- Action
- appointed
- Role
- Director
Exact text from the filing
Immediately following the Effective Time, Matthew C. Abernethy and Darin M. Lippoldt became the directors of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Meredith Manning resigned as Chief Commercial Officer at SOLENO THERAPEUTICS INC.
- Action
- resigned
- Role
- Chief Commercial Officer
Exact text from the filing
each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Manher (AJ) Joshi resigned as Chief Development Officer at SOLENO THERAPEUTICS INC.
- Action
- resigned
- Role
- Chief Development Officer
Exact text from the filing
each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Birgitte Volck resigned as Director at SOLENO THERAPEUTICS INC.
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair and Dawn Bir resigned from his or her respective positions as a member of the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael Huang resigned as Senior Vice President, Clinical Development at SOLENO THERAPEUTICS INC.
- Action
- resigned
- Role
- Senior Vice President, Clinical Development
Exact text from the filing
each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Darin M. Lippoldt was appointed as Director at SOLENO THERAPEUTICS INC.
- Action
- appointed
- Role
- Director
Exact text from the filing
Immediately following the Effective Time, Matthew C. Abernethy and Darin M. Lippoldt became the directors of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dawn Bir resigned as Director at SOLENO THERAPEUTICS INC.
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair and Dawn Bir resigned from his or her respective positions as a member of the Company’s board of directors
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
SOLENO THERAPEUTICS INC: The company's bylaws were amended and restated in their entirety.
- Change
- bylaw amendment
Exact text from the filing
the Company’s certificate of incorporation and bylaws were each amended and restated in their entirety
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
SOLENO THERAPEUTICS INC: The company's certificate of incorporation was amended and restated in its entirety.
- Change
- charter amendment
Exact text from the filing
the Company’s certificate of incorporation and bylaws were each amended and restated in their entirety
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
SOLENO THERAPEUTICS INC underwent a change of control involving Neurocrine Biosciences, Inc. for $53.00 per Share in cash (closed 2026-05-18).
- Action
- change of control
- Counterparty
- Neurocrine Biosciences, Inc.
- Consideration
- $53.00 per Share in cash
- Closing
- 2026-05-18
Exact text from the filing
a tender offer (the “Offer”) to purchase all of the issued and outstanding shares of the common stock of the Company, par value $0.001 per share (the “Shares”), in exchange for $53.00 per Share in cash, without interest (the “Offer Price”), subject to any applicable withholding taxes. The Offer expired as scheduled one minute following 11:59 p.m. Eastern Time
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
SOLENO THERAPEUTICS INC terminated 2014 Employee Stock Purchase Plan.
- Action
- termination
- Agreement
- equity purchase
Exact text from the filing
In accordance with the terms of the Merger Agreement, effective immediately prior to the Effective Time, the Company terminated its 2014 Employee Stock Purchase Plan (the "ESPP").
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
SOLENO THERAPEUTICS INC terminated Loan and Security Agreement with Oxford Finance LLC, as collateral agent (effective 2026-05-18).
- Action
- termination
- Agreement
- credit facility
- Counterparty
- Oxford Finance LLC, as collateral agent
- Effective
- 2026-05-18
Exact text from the filing
On May 18, 2026, in connection with the Merger, the Company, as borrower, terminated the Loan and Security Agreement, dated as of December 17, 2024, as amended, by and among the Company, Essentialis, Inc., the lenders from time to time party thereto and Oxford Finance LLC, as collateral agent (the "Loan and Security Agreement").
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.